New treatment approaches in chronic kidney disease-associated anaemia

Bibliography

• Mcclellan WM, Aronoff SL, Bolton WK. The prevalence of anaemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-10
   PubMed Web of Science ®Google Scholar
• Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study DOPPS). Nephrol Dial Transplant 2004;19:121-32
   PubMed Web of Science ®Google Scholar
• KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012;2(4):279-335
   Google Scholar
• Pisoni RL, Fuller DS, Bieber BA, et al. The DOPPS Practice Monitor for US dialysis care: trends through August 2011. Am J Kidney Dis 2012;60(1):160-5
   PubMed Web of Science ®Google Scholar
• Available from: http://omontys.com/ [Last accessed 26 February 2013]
   Google Scholar
• Storring PL, Tiplady RJ, Gaines Das RE, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100:79-89
   PubMed Web of Science ®Google Scholar
• Del Vecchio L, Locatelli F. Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease. Expert Opin Drug Saf 2012;11(6):923-31
   PubMed Web of Science ®Google Scholar
• Livnah O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996;273(5274):464-71
   PubMed Web of Science ®Google Scholar
• Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996;273(5274):458-64
   PubMed Web of Science ®Google Scholar
• Johnson DL, Farrell FX, Barbone FP, et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry 1998;37(11):3699-710
   PubMed Web of Science ®Google Scholar
• Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006;34(10):1303-11
   PubMed Web of Science ®Google Scholar
• Bugelski PJ, Capocasale RJ, Makropoulos D, et al. CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. J Biotechnol 2008;134(1-2):171-80
   PubMed Web of Science ®Google Scholar
• Scully MS, Ort TA, James IE, et al. A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes. Exp Diabetes Res 2011;2011:910159
   PubMedGoogle Scholar
• Bugelski PJ, Makropoulos D, Spinka-Doms T, et al. Differential effects of long-lived erythropoietin receptor agonists in rats. Anal Acta 2011;2:7
   Google Scholar
• Pérez-Ruixo JJ, Krzyzanski W, Bouman-Thio E, et al. Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects. Clin Pharmacokinet 2009;48(9):601-13
   PubMed Web of Science ®Google Scholar
• Bouman-Thio E, Franson K, Miller B, et al. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J Clin Pharmacol 2008;48(10):1197-207
   PubMed Web of Science ®Google Scholar
• Sytkowski AJ, Lunn ED, Davis KL, et al. Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci USA 1998;95:1184-8
   PubMed Web of Science ®Google Scholar
• Dalle B, Henri A, Rouyer-Fessard P, et al. Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood 2001;97(12):3776-82
   PubMed Web of Science ®Google Scholar
• Fares F, Ganem S, Hajouj T, Agai E. Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of human erythropoietin. Endocrinology 2007;148(10):5081-7
   PubMed Web of Science ®Google Scholar
• Fares F, Havron A, Fima E. Designing a long acting erythropoietin by fusing three carboxyl-terminal peptides of human chorionic gonadotropin β subunit to the n-terminal and c-terminal coding sequence. Int J Cell Biol 2011;2011:275063
   PubMedGoogle Scholar
• Schriebl K, Trummer E, Lattenmayer C, et al. Biochemical characterization of rhEpo-Fc fusion protein expressed in CHO cells. Protein Expr Purif 2006;49(2):265-75
   PubMed Web of Science ®Google Scholar
• Way JC, Lauder S, Brunkhorst B, et al. Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng Des Sel 2005;18:111-18
   PubMed Web of Science ®Google Scholar
• Penno CA, Kawabe Y, Ito A, Kamihira M. Production of recombinant human erythropoietin/Fc fusion protein by genetically manipulated chickens. Transgenic Res 2010;19(2):187-95
   PubMed Web of Science ®Google Scholar
• Joung CH, Shin JY, Koo JK, et al. Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell. Protein Expr Purif 2009;68(2):137-45
   PubMed Web of Science ®Google Scholar
• Coscarella A, Liddi R, Di Loreto M, et al. The rhGM-CSF-EPO hybrid protein MEN 11300 induces anti-EPO antibodies and severe anaemia in rhesus monkeys. Cytokine 1998;10:964-9
   PubMed Web of Science ®Google Scholar
• Schneider H, Chaovapong W, Matthews DJ, et al. Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. Blood 1997;89:473-82
   PubMed Web of Science ®Google Scholar
• Elliott S, Lorenzini T, Yanagihara D, et al. Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies. J Biol Chem 1996;271:24691-7
   PubMed Web of Science ®Google Scholar
• Babcook JS, Leslie KB, Olsen OA, et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci USA 1996;93:7843-8
   PubMed Web of Science ®Google Scholar
• Philo JS, Aoki KH, Arakawa T, et al. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry 1996;35:1681-91
   PubMed Web of Science ®Google Scholar
• Lacy SE, DeVries PJ, Xie N, et al. The potency of erythropoietin-mimic antibodies correlates inversely with affinity. J Immunol 2008;181(2):1282-7
   PubMed Web of Science ®Google Scholar
• Maguer-Satta V, Bartholin L, Jeanpierre S, et al. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. Exp Cell Res 2003;282:110-20
   PubMed Web of Science ®Google Scholar
• Lotinun S, Pearsall RS, Davies MV, et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010;46:1082-8
   PubMed Web of Science ®Google Scholar
• Finberg KE, Whittlesey RL, Fleming MD, Andrews NC. Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood 2010;115(18):3817-26
   PubMed Web of Science ®Google Scholar
• Iancu-Rubin C, Mosoyan G, Wang J, et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol 2013;41(2):155-66
   PubMed Web of Science ®Google Scholar
• Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 2009;24(4):744-52
   PubMed Web of Science ®Google Scholar
• Raje N, Vallet S. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010;12(5):586-97
   PubMed Web of Science ®Google Scholar
• Zhou L, McMahon C, Bhagat T, et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res 2011;71(3):955-63
   PubMed Web of Science ®Google Scholar
• Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010;40(2):294-309
   PubMed Web of Science ®Google Scholar
• Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012;148(3):399-408
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30(4):393-402
   PubMed Web of Science ®Google Scholar
• Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA 2006;103:654-9
   PubMed Web of Science ®Google Scholar
• Takeda K, Aguila HL, Parikh NS, et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 2008;111(6):3229-35
   PubMed Web of Science ®Google Scholar
• Yoji AM, Kaelin WG Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science 2010;329(5990):407
   PubMed Web of Science ®Google Scholar
• Minamishima YA, Moslehi J, Bardeesy N, et al. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 2008;111(6):3236-44
   PubMed Web of Science ®Google Scholar
• Provenzano R, et al. Pharmacokinetics of oral FG-4592 to treat anemia in hemodialysis patients [abstract 189]. National Kidney Foundation Conference; 2011
   Google Scholar
• Besarab A, Hulter HN, Klaus S, et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients [abstract SA-FC416]. American Society of nephrology Renal Week; 16 – 21 November 2010; Denver (CO), USA
   Google Scholar
• Provenzano R, et al. Evaluation of FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor, to treat anemia in hemodialysis patients [abstract 188]. National Kidney Foundation Conference; 2011
   Google Scholar
• Besarab A, Chernyavskaya EN, Motylev I, et al. FG-4592, an oral hypoxia-inducible factor propyl hydroxylase inhibitor, corrects anemia without iron supplementation in incident dialysis patients. J Am Soc Nephrol 2012;23:abstract 21A
   Google Scholar
• Besarab A, Tak Mao Chan D, Dua SL, et al. Hypoxia inducing factor propyl hydroxylase inhibitor FG-4592 corrects anemia in peritoneal dialysis. J Am Soc Nephrol 2013;24:abstract 91A
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/results?term=AKB-6548+&Search=Search [Last accessed 15 October 2013]
   Google Scholar
• Available from: http://www.businesswire.com/news/home/20120405005347/en/Akebia-Meets-Primary-Endpoint-Phase-2-Study [Last accessed 15 October 2013]
   Google Scholar
• Available from: http://www.pharmabiz.com/NewsDetails.aspx?aid=76706&sid=2 [Last accessed 15 October 2013]
   Google Scholar
• Okumura CY, Hollands A, Tran DN, et al. A new pharmacological agent (AKB-4924) stabilizes hypoxia inducible factor-1 (HIF-1) and increases skin innate defenses against bacterial infection. J Mol Med (Berl) 2012;90(9):1079-89
   PubMed Web of Science ®Google Scholar
• Available from: http://www.gsk-clinicalstudyregister.com/result_comp_list.jsp?compound=GSK1278863 [Last accessed 15 October 2013]
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT01406340?term=GSK1278863&rank=7 [Last accessed 15 October 2013]
   Google Scholar
• Available from: http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=114272&studyId=06119F41-7DBB-405A-BC61-B2AF913A328C&compound=GSK1278863 [Last accessed 15 October 2013]
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT01831804?term=GSK1278863&rank=6 [Last accessed 15 October 2013]
   Google Scholar
• Boettcher MF, Lentini S, Kaiser A, et al. First-in-man studt with BAY 85-3934 – a new oral selective HIF-PH inhibitor for the treatment of oral anemia [abstract]. J Am Soc Nephrol 2013;24:347a
   Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, et al.; TREAT investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361(21):2019-32
   PubMed Web of Science ®Google Scholar
• Locatelli F, Andrulli S, Memoli B, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 2006;21(4):991-8
   PubMed Web of Science ®Google Scholar
• Locatelli F, Aljama P, Canaud B, et al.; Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the trial to reduce cardiovascular events with aranesp therapy (TREAT) study. Nephrol Dial Transplant 2010;25(9):2846-50
   PubMed Web of Science ®Google Scholar
• Locatelli F, Bárány P, Covic A, et al.; ERA-EDTA ERBP Advisory Board. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a european renal best practice position statement. Nephrol Dial Transplant 2013;28(6):1346-59
   PubMed Web of Science ®Google Scholar
• Xu Y, Ding XQ, Zou JZ, et al. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation. J Int Med Res 2011;39(5):1961-7
   PubMed Web of Science ®Google Scholar
• Kuragano T, Itoh K, Shimonaka Y, et al. Hepcidin as well as TNF-alpha are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 2011;26(8):2663-7
   PubMed Web of Science ®Google Scholar
• Hsieh YP, Huang CH, Lee CY, et al. Hepcidin-25 negatively predicts left ventricular mass index in chronic kidney disease patients. World J Nephrol 2013;2(2):38-43
   Google Scholar
• Nakanishi T, Hasuike Y, Otaki Y, et al. Hepcidin: another culprit for complications in patients with chronic kidney disease? Nephrol Dial Transplant 2011;26(10):3092-100
   PubMed Web of Science ®Google Scholar